{"id":758711,"date":"2023-05-15T07:33:23","date_gmt":"2023-05-15T11:33:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"},"modified":"2023-05-15T07:33:23","modified_gmt":"2023-05-15T11:33:23","slug":"bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","title":{"rendered":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PALO ALTO, Calif., May  15, 2023  (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CAN<em>aspire<\/em>, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 \u2013 20, 2023.<\/p>\n<p>Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy.<\/p>\n<p>\n        <strong><br \/>\n          <u>Oral presentation details:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Initial biomarker and clinical findings from the CAN<\/strong><br \/>\n        <strong><br \/>\n          <em>aspire<\/em><br \/>\n        <\/strong><br \/>\n        <strong> Canavan disease gene therapy trial: Exploration of connections between NAA and disease severity<\/strong><br \/>\n        <br \/>\n        <strong>Presenter: <\/strong>Florian Eichler, M.D., director of the leukodystrophy service at Massachusetts General Hospital, Center for Rare Neurological Disease and lead CAN<em>aspire<\/em> investigator<br \/><strong>Session date\/ time: <\/strong>Saturday, May 20 at 10:15 am \u2013 12:00 pm PT<br \/><strong>Presentation time: <\/strong>11:15 am \u2013 11:30 am PT<br \/><strong>Location: <\/strong>Concourse Hall 150 &amp; 151, Los Angeles Convention Center<br \/><strong>Session title: <\/strong>Gene and cell therapy trials in progress<br \/><strong>Abstract number: <\/strong>358<\/p>\n<p>\n        <strong><br \/>\n          <u>Additional panel details:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Accelerated approval for cell and gene therapies<\/strong><br \/>\n        <br \/>\n        <strong>Date &amp; time:<\/strong> Wednesday, May 17 at 9:00 am \u2013 9:45 am PT<br \/><strong>Panelist:<\/strong> Adora Ndu, Pharm.D., J.D., chief regulatory and interim legal officer of BridgeBio<br \/><strong>Location: <\/strong>Room 515 AB, Los Angeles Convention Center<\/p>\n<p>\n        <strong>Venture capital in the gene and cell therapy space<\/strong><br \/>\n        <br \/>\n        <strong>Date &amp; time:<\/strong> Friday, May 19 at 8:00 am \u2013 9:45 am PT<br \/><strong>Co-chair: <\/strong>Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy<br \/><strong>Panelist:<\/strong> Neil Kumar, Ph.D., founder and CEO of BridgeBio<br \/><strong>Location: <\/strong>Concourse Hall 152 &amp; 153, Los Angeles Convention Center<\/p>\n<p>\n        <strong>Evolution of genetic medicines: Navigating the challenges and synergies among therapeutic modalities<\/strong><br \/>\n        <br \/>\n        <strong>Date &amp; time: <\/strong>Friday, May 19 at 10:15 am \u2013 12:30 pm PT <br \/><strong>Panelist:<\/strong> Eric David, M.D., J.D., CEO of BridgeBio Gene Therapy<br \/><strong>Location: <\/strong>Room 411, Los Angeles Convention Center<\/p>\n<p>\n        <strong>Accelerate your drug development program in rare disease with robust natural history data: An evolving space<\/strong><br \/>\n        <br \/>\n        <strong>Session title: <\/strong>How to design a natural history study that regulators and clinicians support<br \/><strong>Date &amp; time:<\/strong> Friday, May 19 at 10:15 am \u2013 12:00 pm PT<br \/><strong>Panelist:<\/strong> Adam Shaywitz, M.D., Ph.D., chief medical officer at BridgeBio Gene Therapy<br \/><strong>Location: <\/strong>Room 408 AB, Los Angeles Convention Center<\/p>\n<p>\n        <strong>About BridgeBio Pharma, Inc.<\/strong><br \/>\n        <br \/>BridgeBio Pharma Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8z0aoR7OlKSJPShaufeNnROR1-TXYB_AbHyaKfeY-7q9pLN861uBcfhx6k9igH3XNu27ZHnGP-VgP5PhURbn-g==\" rel=\"nofollow noopener\" target=\"_blank\"><strong>bridgebio.com<\/strong><\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wGQVpp-DcfHfdLXHefQ8ZQtsnsEEeSB8LNzYL8N7hbJkxN6bVJ5fVaIBDWSKy_MOqVxwWR4B2Qgd06Q3zbfMzVK5JrZPGLyplzsBpv0fWBo=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Ph9fZKdCv1aIlpcjTXpSOIVu2FW45gvBN7LuK-T-BCLoRfMOVw-EfUy6VQaqc36xTYLFMOv9rk293kUlht8bHQjv88nWBQmlYHhse2m5vA=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Twitter<\/strong><\/a>.<\/p>\n<p>\n        <strong>BridgeBio Media Contact:<\/strong><br \/>\n        <br \/>Vikram Bali<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nMRcb8IcwsoXRQsjiPFMzBhQ9MSzmwS7SA2fJfoqWRghAD6n_kmFmTW0WgyZ00YgQ3QGXzoM_GjpGgvfPMMz_QAsSHNe-N8y3i-VSBR5-5w=\" rel=\"nofollow noopener\" target=\"_blank\">contact@bridgebio.com<br \/><\/a>(650)-789-8220<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTUwN2I4YjYtOWM1NC00MWFkLWFhYzctNzU0OGZlOTcwMGY1LTExNjg0OTc=\/tiny\/BridgeBio-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 \u2013 20, 2023. Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy. Oral presentation details: Initial biomarker and clinical findings &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758711","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 \u2013 20, 2023. Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy. Oral presentation details: Initial biomarker and clinical findings &hellip; Continue reading &quot;BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-15T11:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\",\"datePublished\":\"2023-05-15T11:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\"},\"wordCount\":501,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\",\"name\":\"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=\",\"datePublished\":\"2023-05-15T11:33:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk","og_description":"PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d),\u00a0a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1\/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 \u2013 20, 2023. Additionally, members of BridgeBio leadership, including Neil Kumar, CEO and founder, will be presenting on multiple panels discussing drug development and accelerated approval for gene therapy. Oral presentation details: Initial biomarker and clinical findings &hellip; Continue reading \"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-15T11:33:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting","datePublished":"2023-05-15T11:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"},"wordCount":501,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/","name":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=","datePublished":"2023-05-15T11:33:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODY4MSM1NTkzNTQ4IzIxNTY5MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-to-present-updated-data-from-its-bbp-812-canavan-disease-gene-therapy-program-at-the-2023-american-society-of-gene-and-cell-therapy-asgct-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758711"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758711\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}